This study is testing a new treatment called AZD0120 for adults with Systemic Lupus Erythematosus (SLE) that hasn't responded to other treatments. AZD0120 is a type of CAR T cell therapy, which uses your own immune cells to fight the disease. Before receiving AZD0120, you would have a short course of chemotherapy with Cyclophosphamide and Fludarabine. Researchers want to see if AZD0120 is safe, how well people tolerate it, and if it helps improve SLE symptoms. The study is open to adults aged 18 to 70 who meet certain health requirements. This study is currently unclear about its recruitment status and plans to enroll about 150 participants.

Study design

This is a Phase 1b/2, single-arm, open-label study, meaning all participants receive the same treatment and both you and the study team will know what treatment you are getting. It plans to enroll about 150 participants.

What's involved

You would receive a single infusion of AZD0120 after completing required lymphodepleting chemotherapy. You would need to follow a specific study visit schedule and other protocol requirements.

Compensation

Not stated in the trial record.

Follow-up

The study will evaluate safety, tolerability, and efficacy for up to 2 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.